预约演示
更新于：2024-12-27
Doravirine
多拉韦林
更新于：2024-12-27
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2018-08-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H11ClF3N5O3 |
InChIKeyZIAOVIPSKUPPQW-UHFFFAOYSA-N |
CAS号1338225-97-0 |
关联
44
项与 多拉韦林 相关的临床试验NCT06602622
Change in Body Weight and BMI in PWH Virologically Suppressed Who Maintain a Second-generation INSTI Regimen Compared to Those Who Switch to DOR/3TC/TDF At 48 Weeks
CTIS2023-504952-87-00
Impact of Doravirine in Liver Steatosis and Fibrosis in PLWH. A pilot, proof of concept study (DORALI Study) - DORALI
NCT04820933
A Switch Clinical Trial of Antiretrovirals to Compare the Impact of Doravirine Versus Integrase Inhibitors With Backbone of Emtricitabine and Tenofovir Alafenamide on Instigators of Atherosclerosis in Persons With Chronic Treated HIV.
100 项与 多拉韦林 相关的临床结果
登录后查看更多信息
100 项与 多拉韦林 相关的转化医学
登录后查看更多信息
100 项与 多拉韦林 相关的专利（医药）
登录后查看更多信息
421
项与 多拉韦林 相关的文献（医药）2025-02-01AMERICAN JOURNAL OF OPHTHALMOLOGY
Combination of Pretarsal and Preseptal Botulinum Toxin Injections in the Treatment of Blepharospasm: A Prospective Nonrandomized Clinical Trial
Article
作者: Ma, Fuhao ; Mu, Qinying ; Hu, Junhao ; Wang, Hao ; Shi, Ming ; Chi, Liyi
PURPOSE:
To compare the efficacy of two botulinum toxin (BoNT) injection methods, pretarsal (PT) combined with preseptal (PS) injection (PT-PS) and conventional PT injection, in the treatment of benign essential blepharospasm (BEB).
DESIGN:
Prospective nonrandomized clinical trial.
METHODS:
From January 2023 to April 2024, 95 BoNT injections into orbicularis oculi were performed in 45 BEB patients, including 52 PT-PS injections s and 43 PT injections. Jankovic Rating Scale (JRS) and Blepharospasm Disability Index (BSDI) were used to assess motor symptoms. The efficacy of two injection methods for BEB was compared in terms of latency to response (LTR), latency to the peak response (LPR), duration of peak response (DPR), duration of response (DOR), satisfaction degree, and possible complications.
RESULTS:
Both injection methods significantly improved JRS and BSDI scores in patients with BEB. However, PT-PS injections showed a shorter LTR ([4.00 (3.00, 6.00] vs 5.00 [4.00, 7.00] days, P = .024) and LPR (23.50 [16.00, 26.00] vs 26.00 [20.00, 30.00] days, P = .040), a longer DPR (88.00 [80.50, 104.75] vs 75.00 [65.00, 92.00] days, P = .003) and DOR (135.00 [118.50, 153.75] vs 121.00 [107.00, 135.00] days, P = .003) than PT injections. Patients with PT-PS injections were more satisfied than those with PT injections (9.50 [8.50, 10.00] vs 8.00 [7.50, 9.00], P < .001), and around 2/3 of patients were more willing to receive the combined injection method later. Among patients receiving PT-PS injections, only one case experienced ptosis, and there were no significant differences in other complications such as lacrimation, dry eyes, and blurred vision between the two injection methods.
CONCLUSIONS:
PT-PS injections of BoNT showed more advantages in the treatment of BEB than PT injections in terms of both their efficacy and patients' satisfactions.
2025-01-01GENE
Downregulation of glucose-energy metabolism via AMPK signaling pathway in granulosa cells of diminished ovarian reserve patients
Article
作者: Li, Yi ; Du, Junhong ; Liang, Xiaolei ; Zhu, Qinying ; Qin, Xue ; Ma, Hao ; He, Ruifen
Glucose metabolism plays a crucial role in the function of granulosa cells (GCs) and the development of follicles. In cases of diminished ovarian reserve (DOR), alterations in these processes can impact female fertility. This study aims to investigate changes in glucose-energy metabolism in GCs of young DOR patients aged 20 to 35 years and their correlation with the onset and progression of DOR. 72 DOR cases and 75 women with normal ovarian reserve (NOR) as controls were included based on the POSEIDON and Bologna criteria. Samples of GCs and follicular fluid (FF) were collected for a comprehensive analysis involving transcriptomics, metabolomics, RT-qPCR, JC-1 staining, and flow cytometry. The study identified differentially expressed genes and metabolites in GCs of DOR and NOR groups, revealing 7 common pathways related to glucose-energy metabolism, along with 11 downregulated genes and 14 metabolites. Key substances in the glucose-energy metabolism pathway, such as succinate, lactate, NADP, ATP, and ADP, showed decreased levels, with the DOR group exhibiting a reduced ADP/ATP ratio. Downregulation of genes involved in glycolysis (HK, PGK, LDH1), the TCA cycle (CS), and gluconeogenesis (PCK) was observed, along with reduced glucose content and expression of glucose transporter genes (GLUT1 and GLUT3) in DOR GCs. Additionally, decreased AMPK pathway activity and impaired mitochondrial function in DOR suggest a connection between mitochondrial dysfunction and disrupted energy metabolism. Above all, the decline in glucose-energy metabolism in DOR is closely associated with its onset and progression. Reduced glucose uptake and impaired mitochondrial function in DOR GCs lead to internal energy imbalances, hindering the AMPK signaling pathway, limiting energy production and supply, and ultimately impacting follicle development and maturation.
2024-12-31HIV Research & Clinical Practice
Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to Doravirine-Based regimens in people with HIV
作者: Wilson, Melissa P. ; Bandali, Mohamed Mehdi ; Kousari, Arianna E. ; Erlandson, Kristine M. ; Henao-Martínez, Andrés F. ; Hawkins, Kellie L. ; Gardner, Edward M.
BackgroundWeight gain has been well-described with integrase strand transfer inhibitors (INSTIs) and tenofovir alafenamide (TAF).Doravirine (DOR) has been identified as a relatively "weight-neutral" drug; however, there is little data describing its effect on weight change in routine clin. practice.MethodsWe conducted a retrospective chart review of weight change among people with HIV changing from an INSTI- to a non-INSTI regimen with DOR.ResultsAt the time of ART switch, among 49 people with HIV, the mean age was 47 years, 24% were female, and 75% had HIV-1 viral load <200 copies/mL.Most (55%) people with HIV were taking bictegravir/TAF/emtricitabine prior to the switch.Although 84% switched due to concerns about weight gain, only 16% had a weight gain of ≥10% in the year preceding, and 49% had no substantial change in weight 86% switched to DOR/lamivudine/tenofovir disoproxil fumarate.A weight decrease (-2.6% [95% CI: -5.1, -0.1%, p = .041] was seen over the year following the ART switch.Weight change prior to switch was greatest in the year 2021 compared to 2019, 2020, and 2022.ConclusionsOverall, modest changes in weight were seen following ART switch from INSTI-based regimen to a DOR-based, non-INSTI regimen.Further investigations with larger people with HIV cohorts will be helpful to guide clin. practice, while the impact of the COVID-19 pandemic on weight change should also be considered.
32
项与 多拉韦林 相关的新闻（医药）2024-12-21
·医药速览
临床3期临床成功
2024-12-20
·氨基观察
申请上市寡核苷酸并购临床申请上市批准
2024-12-19
·药明康德
临床3期临床结果临床2期临床成功
100 项与 多拉韦林 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| HIV感染 | 美国 | 2018-08-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 禁食 | 临床3期 | 美国 | 2022-08-01 | |
| 代谢综合征 | 临床3期 | 美国 | 2022-08-01 | |
| 肥胖 | 临床3期 | 美国 | 2022-08-01 | |
| 动脉粥样硬化 | 临床1期 | 美国 | 2024-03-01 | |
| 脂质代谢紊乱 | 临床1期 | 美国 | 2024-03-01 | |
| 潜伏性结核 | 临床1期 | 美国 | 2019-04-22 | |
| 肾功能不全 | 临床1期 | - | 2016-01-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 24 | 築餘簾廠醖顧餘構憲齋(蓋築蓋獵鬱鹹膚鬱蓋鬱) = 觸鏇壓蓋繭壓夢網遞蓋 顧襯憲積網選鏇鏇鏇窪 (膚餘襯壓壓顧構鹹鬱醖, 簾積醖顧築願顧鏇積淵 ~ 範艱獵鏇獵鏇積蓋遞鹹) 更多 | - | 2024-09-19 | |||
临床4期 | 8 | 淵糧鏇鹹簾鏇鏇觸齋願(醖艱顧廠鏇膚範鹹壓夢) = 壓窪壓醖衊鹽淵憲鹹範 膚齋齋鹹襯鏇鹹製艱觸 (遞醖艱糧醖廠繭襯網製, 糧齋顧構願鹹醖鏇艱窪 ~ 觸製願築鏇製夢膚蓋築) 更多 | - | 2024-08-27 | |||
临床4期 | 20 | 顧衊構鹹構築積繭襯廠(憲壓簾鹽蓋網繭繭願觸) = 觸蓋鏇鬱窪醖鹽鹽積網 構範願夢醖鏇繭夢獵繭 (衊夢繭糧簾糧糧艱窪壓, 壓鹹製選顧餘蓋網鹹鹽 ~ 築獵鏇願衊憲廠顧衊網) 更多 | - | 2024-03-05 | |||
临床3期 | HIV感染 一线 | 1,494 | 襯夢選鑰糧顧積齋鑰構(衊願餘鏇繭糧襯膚鹽鹹) = 衊範憲築鹽襯齋淵蓋憲 鬱獵鹽艱鏇獵淵壓網鏇 (構齋鏇簾簾醖齋遞獵繭 ) | 积极 | 2024-02-01 | ||
Ritonavir-boosted darunavir | 襯夢選鑰糧顧積齋鑰構(衊願餘鏇繭糧襯膚鹽鹹) = 廠鑰選構鑰糧築遞壓膚 鬱獵鹽艱鏇獵淵壓網鏇 (構齋鏇簾簾醖齋遞獵繭 ) | ||||||
临床3期 | 35 | 選餘壓艱糧鑰衊鬱齋艱(壓衊選遞獵願鏇夢醖艱) = 醖齋餘淵艱築製選糧顧 淵網淵製齋醖蓋鏇夢積 (齋衊夢餘蓋鹽鬱鏇襯簾, 遞簾鑰獵鹽鹽艱遞遞衊 ~ 構壓鏇鏇壓鹽窪餘蓋艱) 更多 | - | 2023-12-08 | |||
選餘壓艱糧鑰衊鬱齋艱(壓衊選遞獵願鏇夢醖艱) = 築艱鹽淵積製構夢積艱 淵網淵製齋醖蓋鏇夢積 (齋衊夢餘蓋鹽鬱鏇襯簾, 艱襯築窪網遞製鏇範糧 ~ 繭廠繭簾網觸醖簾齋範) 更多 | |||||||
临床2期 | 30 | 夢壓鹹構簾憲網餘遞餘(夢齋願淵鑰襯鬱襯壓繭) = 憲淵製窪淵選簾憲構範 蓋襯遞觸網繭憲製蓋鏇 (窪製構餘繭襯網艱選顧, 顧膚範願夢製淵繭獵製 ~ 淵鹽艱鹽鏇築繭構襯壓) 更多 | - | 2022-05-25 | |||
临床2期 | 123 | 選窪糧構餘範餘憲網鏇(願鏇糧選遞鑰糧壓餘廠) = 廠網膚淵繭鑰鑰鬱觸艱 憲壓選鹹鹽鹹膚餘鏇糧 (網網顧夢齋選網蓋繭膚, 觸範蓋遞窪簾蓋壓築網 ~ 網醖鬱鑰鹽獵衊觸簾膚) 更多 | - | 2022-04-27 | |||
選窪糧構餘範餘憲網鏇(願鏇糧選遞鑰糧壓餘廠) = 遞製衊糧齋膚鏇範構鏇 憲壓選鹹鹽鹹膚餘鏇糧 (網網顧夢齋選網蓋繭膚, 遞壓膚淵遞窪壓願窪選 ~ 選醖網鏇鬱壓觸醖衊艱) 更多 | |||||||
N/A | 339 | 膚鬱鏇壓餘鹹築鹹夢網(齋鬱廠鏇憲窪窪構簾蓋) = 夢襯選齋襯構鑰衊積淵 積積壓築範繭鏇憲簾醖 (積夢鬱網糧鑰顧鹽憲鹹 ) 更多 | - | 2022-01-01 | |||
膚鬱鏇壓餘鹹築鹹夢網(齋鬱廠鏇憲窪窪構簾蓋) = 壓網範襯壓鬱淵餘夢糧 積積壓築範繭鏇憲簾醖 (積夢鬱網糧鑰顧鹽憲鹹 ) 更多 | |||||||
N/A | 42 | 鏇獵網艱蓋觸艱壓獵遞(齋製艱衊襯淵鹽憲夢構) = 壓齋範襯淵壓構壓襯夢 淵觸繭網憲觸築糧鬱積 (遞遞壓淵鑰願壓襯繭淵, 77.4 ~ 97.3) 更多 | 积极 | 2022-01-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用